FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134729076> ?p ?o ?g. }

• W2134729076 endingPage "274" @default.
• W2134729076 startingPage "264" @default.
• W2134729076 abstract "Recently, gene-based cytokine treatment has been actively pursued as a new promising approach in treating cancer. In an effort to augment the efficiency of antitumor effect by cytokine-mediated immunotherapy, we selected both interleukin (IL)-12 and 4-1BB ligand (4-1BBL) as suitable cytokines to fully activate the type-1 immune response. Coexpression of IL-12 and 4-1BBL mediated by oncolytic adenovirus (Ad) greatly enhanced the antitumor effect. Further, synergistic enhancement in interferon (IFN)-γ levels were seen in mice treated with oncolytic Ad expressing both IL-12 and 4-1BBL. Next, to improve the overall antitumor immune response, we coadministered IL-12- and 4-1BBL-coexpressing oncolytic Ad with dendritic cells (DCs). Combination treatment of IL-12- and 4-1BBL-coexpressing oncolytic Ad and DCs elicited greater antitumor and antimetastatic effects than either treatment alone. Moreover, enhanced type-1 antitumor immune response and higher migratory abilities of DCs in tumors were also observed in the combination arms. The nature of the enhanced antitumor immune response seems to be mediated through the enhanced cytolytic activity of cytotoxic T lymphocytes (CTLs) and IFN-γ-releasing immune cells. Taken together, these data highlight the potential therapeutic benefit of combining IL-12- and 4-1BBL-coexpressing oncolytic Ad with DCs and warrants further evaluation in the clinic. Recently, gene-based cytokine treatment has been actively pursued as a new promising approach in treating cancer. In an effort to augment the efficiency of antitumor effect by cytokine-mediated immunotherapy, we selected both interleukin (IL)-12 and 4-1BB ligand (4-1BBL) as suitable cytokines to fully activate the type-1 immune response. Coexpression of IL-12 and 4-1BBL mediated by oncolytic adenovirus (Ad) greatly enhanced the antitumor effect. Further, synergistic enhancement in interferon (IFN)-γ levels were seen in mice treated with oncolytic Ad expressing both IL-12 and 4-1BBL. Next, to improve the overall antitumor immune response, we coadministered IL-12- and 4-1BBL-coexpressing oncolytic Ad with dendritic cells (DCs). Combination treatment of IL-12- and 4-1BBL-coexpressing oncolytic Ad and DCs elicited greater antitumor and antimetastatic effects than either treatment alone. Moreover, enhanced type-1 antitumor immune response and higher migratory abilities of DCs in tumors were also observed in the combination arms. The nature of the enhanced antitumor immune response seems to be mediated through the enhanced cytolytic activity of cytotoxic T lymphocytes (CTLs) and IFN-γ-releasing immune cells. Taken together, these data highlight the potential therapeutic benefit of combining IL-12- and 4-1BBL-coexpressing oncolytic Ad with DCs and warrants further evaluation in the clinic." @default.
• W2134729076 created "2016-06-24" @default.
• W2134729076 creator A5000975574 @default.
• W2134729076 creator A5005358526 @default.
• W2134729076 creator A5023568164 @default.
• W2134729076 creator A5024716487 @default.
• W2134729076 creator A5026148041 @default.
• W2134729076 creator A5028862643 @default.
• W2134729076 creator A5031646590 @default.
• W2134729076 creator A5069077125 @default.
• W2134729076 date "2010-02-01" @default.
• W2134729076 modified "2023-10-16" @default.
• W2134729076 title "Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL" @default.
• W2134729076 cites W1483299903 @default.
• W2134729076 cites W1502235898 @default.
• W2134729076 cites W1524274652 @default.
• W2134729076 cites W1544229812 @default.
• W2134729076 cites W1568098880 @default.
• W2134729076 cites W1609710757 @default.
• W2134729076 cites W1789525127 @default.
• W2134729076 cites W1893411048 @default.
• W2134729076 cites W1963964961 @default.
• W2134729076 cites W1973737079 @default.
• W2134729076 cites W1975060729 @default.
• W2134729076 cites W1976899534 @default.
• W2134729076 cites W1980529587 @default.
• W2134729076 cites W1984484036 @default.
• W2134729076 cites W1998006783 @default.
• W2134729076 cites W2015813864 @default.
• W2134729076 cites W2017968822 @default.
• W2134729076 cites W2019534018 @default.
• W2134729076 cites W2022521773 @default.
• W2134729076 cites W2023902508 @default.
• W2134729076 cites W2024422011 @default.
• W2134729076 cites W2033614281 @default.
• W2134729076 cites W2044560381 @default.
• W2134729076 cites W2071322585 @default.
• W2134729076 cites W2072685090 @default.
• W2134729076 cites W2092768308 @default.
• W2134729076 cites W2099061536 @default.
• W2134729076 cites W2102051326 @default.
• W2134729076 cites W2103033656 @default.
• W2134729076 cites W2115791536 @default.
• W2134729076 cites W2119897005 @default.
• W2134729076 cites W2121672863 @default.
• W2134729076 cites W2122937303 @default.
• W2134729076 cites W2127470843 @default.
• W2134729076 cites W2134532807 @default.
• W2134729076 cites W2142943268 @default.
• W2134729076 cites W2149234550 @default.
• W2134729076 cites W2152627678 @default.
• W2134729076 cites W2162620875 @default.
• W2134729076 doi "https://doi.org/10.1038/mt.2009.205" @default.
• W2134729076 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2839296" @default.
• W2134729076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19738604" @default.
• W2134729076 hasPublicationYear "2010" @default.
• W2134729076 type Work @default.
• W2134729076 sameAs 2134729076 @default.
• W2134729076 citedByCount "112" @default.
• W2134729076 countsByYear W21347290762012 @default.
• W2134729076 countsByYear W21347290762013 @default.
• W2134729076 countsByYear W21347290762014 @default.
• W2134729076 countsByYear W21347290762015 @default.
• W2134729076 countsByYear W21347290762016 @default.
• W2134729076 countsByYear W21347290762017 @default.
• W2134729076 countsByYear W21347290762018 @default.
• W2134729076 countsByYear W21347290762019 @default.
• W2134729076 countsByYear W21347290762020 @default.
• W2134729076 countsByYear W21347290762021 @default.
• W2134729076 countsByYear W21347290762022 @default.
• W2134729076 countsByYear W21347290762023 @default.
• W2134729076 crossrefType "journal-article" @default.
• W2134729076 hasAuthorship W2134729076A5000975574 @default.
• W2134729076 hasAuthorship W2134729076A5005358526 @default.
• W2134729076 hasAuthorship W2134729076A5023568164 @default.
• W2134729076 hasAuthorship W2134729076A5024716487 @default.
• W2134729076 hasAuthorship W2134729076A5026148041 @default.
• W2134729076 hasAuthorship W2134729076A5028862643 @default.
• W2134729076 hasAuthorship W2134729076A5031646590 @default.
• W2134729076 hasAuthorship W2134729076A5069077125 @default.
• W2134729076 hasBestOaLocation W21347290761 @default.
• W2134729076 hasConcept C149532602 @default.
• W2134729076 hasConcept C154317977 @default.
• W2134729076 hasConcept C202751555 @default.
• W2134729076 hasConcept C203014093 @default.
• W2134729076 hasConcept C2777283488 @default.
• W2134729076 hasConcept C2777701055 @default.
• W2134729076 hasConcept C2778690821 @default.
• W2134729076 hasConcept C2780674031 @default.
• W2134729076 hasConcept C502942594 @default.
• W2134729076 hasConcept C55493867 @default.
• W2134729076 hasConcept C74172505 @default.
• W2134729076 hasConcept C82210918 @default.
• W2134729076 hasConcept C86803240 @default.
• W2134729076 hasConcept C8891405 @default.
• W2134729076 hasConcept C98119934 @default.
• W2134729076 hasConceptScore W2134729076C149532602 @default.
• W2134729076 hasConceptScore W2134729076C154317977 @default.

• next